BIO-TECHNE Corp Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-09-13: Measure Organic Revenue Growth.
- 2023-09-13: Measure Adjusted Net Income.
- 2024-09-12: Measure Organic Revenue Growth.
- 2024-09-12: Measure Adjusted Net Income.
| Proxy filed | Measure |
|---|---|
| 2023-09-13 | Organic Revenue Growth |
| 2023-09-13 | Adjusted Net Income |
| 2024-09-12 | Organic Revenue Growth |
| 2024-09-12 | Adjusted Net Income |
| 2025-09-19 | Organic Revenue |
| 2025-09-19 | Adjusted Net Income |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |